Dr. de Juan receives Catalyst Award; opera singer Márquez gets Visionary Award
A renowned ophthalmologist and an accomplished opera singer were the highlight of Thursday night’s Glaucoma 360 annual Gala, when the two were presented with the Glaucoma Research Foundation’s (GRF) highest honors—The Catalyst Award and Visionary Award.
Eugene de Juan Jr., MD, one of the world’s foremost ophthalmic innovators, surgeons, researchers, and entrepreneurs, received the Catalyst Award in recognition of his outstanding leadership and commitment to advancing ophthalmology. Dr. de Juan is the Jean Kelly Stock Distinguished Professor of Ophthalmology, University of California, San Francisco, and founder and vice chairman of ForSight Labs.
“Dr. de Juan is an extraordinary physician and teacher, as well as a successful entrepreneur,” said Thomas M. Brunner, president and chief executive officer of GRF. “He has dedicated his career to the development of new and innovative technologies to preserve vision. GRF is thrilled to have this opportunity to recognize Gene for his many contributions to medicine and improving the lives of patients with blinding eye diseases.”
Dr. de Juan’s career spans more than 30 years as innovator and clinician. As a retina specialist, Dr. de Juan has developed many procedures and devices to treat retinal disorders, including macular translocation, pharmaceuticals, retinal implants, retinal transplantation, and robotic surgery.
Holding more than 50 patents for various medical devices, he has been influential in the development of more than 100 medical technologies, including surgical instruments, biochemical therapies, and complex microcircuitry. Dr. de Juan’s research over the years also has included advancements in ocular drug delivery for age-related macular degeneration.
As an entrepreneur, Dr. de Juan has founded many medical companies, including Nexis Vision Inc. (formerly ForSight VISION3 Inc.), ForSight VISION4 Inc., and ForSight VISION5 Inc. His other ventures include: InnoRx, NeoVista, Retina Labs, Second Sight, Transcend Medical Inc., and VISION2.